437 related articles for article (PubMed ID: 16012762)
1. Long-term follow-up of Japanese patients with chronic hepatitis B treated with interferon-alpha.
Truong BX; Seo Y; Kato M; Hamano K; Ninomiya T; Katayama M; Kato H; Yano Y; Hayashi Y; Kasuga M
Int J Mol Med; 2005 Aug; 16(2):279-84. PubMed ID: 16012762
[TBL] [Abstract][Full Text] [Related]
2. Long-term follow-up of interferon alfa treatment in Chinese patients with chronic hepatitis B infection: The effect on hepatitis B e antigen seroconversion and the development of cirrhosis-related complications.
Yuen MF; Hui CK; Cheng CC; Wu CH; Lai YP; Lai CL
Hepatology; 2001 Jul; 34(1):139-45. PubMed ID: 11431745
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of long-term interferon therapy in chronic hepatitis B patients with HBV genotype C.
Sakai T; Shiraki K; Inoue H; Okano H; Deguchi M; Sugimoto K; Ohmori S; Murata K; Nakano T
Int J Mol Med; 2002 Aug; 10(2):201-4. PubMed ID: 12119559
[TBL] [Abstract][Full Text] [Related]
4. Early response to interferon alpha treatment and long-term clinical outcome in Japanese patients with chronic HBV genotype C infection.
Seo Y; Yoon S; Hamano K; Nakaji M; Yano Y; Katayama M; Ninomiya T; Hayashi Y; Kasuga M
Int J Mol Med; 2004 Jan; 13(1):75-9. PubMed ID: 14654974
[TBL] [Abstract][Full Text] [Related]
5. Higher efficacy of sequential therapy with interferon-alpha and lamivudine combination compared to lamivudine monotherapy in HBeAg positive chronic hepatitis B patients.
Sarin SK; Kumar M; Kumar R; Kazim SN; Guptan RC; Sakhuja P; Sharma BC
Am J Gastroenterol; 2005 Nov; 100(11):2463-71. PubMed ID: 16279901
[TBL] [Abstract][Full Text] [Related]
6. Comparison of interferon and lamivudine treatment in Japanese patients with HBeAg positive chronic hepatitis B.
Arase Y; Ikeda K; Suzuki F; Suzuki Y; Kobayashi M; Akuta N; Hosaka T; Sezaki H; Yatsuji H; Kawamura Y; Kobayashi M; Kumada H
J Med Virol; 2007 Sep; 79(9):1286-92. PubMed ID: 17607775
[TBL] [Abstract][Full Text] [Related]
7. Comparative study of genotype B and C hepatitis B virus-induced chronic hepatitis in relation to the basic core promoter and precore mutations.
Watanabe K; Takahashi T; Takahashi S; Okoshi S; Ichida T; Aoyagi Y
J Gastroenterol Hepatol; 2005 Mar; 20(3):441-9. PubMed ID: 15740490
[TBL] [Abstract][Full Text] [Related]
8. Clinical significance and evolution of core promoter and precore mutations in HBeAg-positive patients with HBV genotype B and C: a longitudinal study.
Chen CH; Lee CM; Hung CH; Hu TH; Wang JH; Wang JC; Lu SN; Changchien CS
Liver Int; 2007 Aug; 27(6):806-15. PubMed ID: 17617124
[TBL] [Abstract][Full Text] [Related]
9. [Study of the relapse of patients with chronic hepatitis B undergoing first and repeated recombinant interferon-alpha therapy during long-term follow up].
Liu DL; Luo KX; Feng XR; Fu QX; Hou JL
Zhonghua Yi Xue Za Zhi; 2007 Jul; 87(26):1840-3. PubMed ID: 17922996
[TBL] [Abstract][Full Text] [Related]
10. Association of core promoter mutations with viral breakthrough in chronic hepatitis B patients on long-term lamivudine therapy.
Kazim SN; Chauhan R; Das BC; Sarin SK
J Gastroenterol Hepatol; 2006 Oct; 21(10):1525-32. PubMed ID: 16928212
[TBL] [Abstract][Full Text] [Related]
11. Response to interferon-alpha in chronic hepatitis B patients with and without precore mutant strain and effects on HBsAg titers.
Akhan SC; Yulugkural Z; Vahaboglu H
Chemotherapy; 2007; 53(6):402-6. PubMed ID: 17934260
[TBL] [Abstract][Full Text] [Related]
12. Long-term follow-up of alpha-interferon treatment of patients with chronic hepatitis B.
van Zonneveld M; Honkoop P; Hansen BE; Niesters HG; Darwish Murad S; de Man RA; Schalm SW; Janssen HL
Hepatology; 2004 Mar; 39(3):804-10. PubMed ID: 14999700
[TBL] [Abstract][Full Text] [Related]
13. Interferon therapy in HBeAg positive chronic hepatitis reduces progression to cirrhosis and hepatocellular carcinoma.
Lin SM; Yu ML; Lee CM; Chien RN; Sheen IS; Chu CM; Liaw YF
J Hepatol; 2007 Jan; 46(1):45-52. PubMed ID: 17107734
[TBL] [Abstract][Full Text] [Related]
14. Favorable efficacy of long-term lamivudine therapy in patients with chronic hepatitis B: an 8-year follow-up study.
Akuta N; Suzuki F; Suzuki Y; Sezaki H; Hosaka T; Someya T; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Kobayashi M; Kumada H
J Med Virol; 2005 Apr; 75(4):491-8. PubMed ID: 15714490
[TBL] [Abstract][Full Text] [Related]
15. [Factors related to chronic hepatitis B relapse after interferon-alpha treatment: a follow-up study].
Liu DL; Luo KX; Feng XR; Fu QX; Hou JL
Nan Fang Yi Ke Da Xue Xue Bao; 2007 Aug; 27(8):1264-6, 1270. PubMed ID: 17715044
[TBL] [Abstract][Full Text] [Related]
16. Individualization of interferon therapy using serum hepatitis B virus DNA to reduce viral relapse in patients with chronic hepatitis B: a randomized controlled trial.
Chung YH; Song BC; Lee GC; Shin JW; Ryu SH; Jung SA; Yoo K; Lee HC; Lee YS; Suh DJ
Eur J Gastroenterol Hepatol; 2003 May; 15(5):489-93. PubMed ID: 12702905
[TBL] [Abstract][Full Text] [Related]
17. A 13-year longitudinal study of the impact of double mutations in the core promoter region of hepatitis B virus on HBeAg seroconversion and disease progression in patients with genotype C chronic active hepatitis.
Jang JW; Lee YC; Kim MS; Lee SY; Bae SH; Choi JY; Yoon SK
J Viral Hepat; 2007 Mar; 14(3):169-75. PubMed ID: 17305882
[TBL] [Abstract][Full Text] [Related]
18. Genetic characteristics of hepatitis B virus genotypes as a factor for interferon-induced HBeAg clearance.
Hou J; Schilling R; Janssen HL; Hansen BE; Heijtink R; Sablon E; Williams R; Lau GK; Schalm SW; Naoumov NV
J Med Virol; 2007 Aug; 79(8):1055-63. PubMed ID: 17596838
[TBL] [Abstract][Full Text] [Related]
19. Long-term outcome of hepatitis B e antigen-positive patients with compensated cirrhosis treated with interferon alfa. European Concerted Action on Viral Hepatitis (EUROHEP).
Fattovich G; Giustina G; Realdi G; Corrocher R; Schalm SW
Hepatology; 1997 Nov; 26(5):1338-42. PubMed ID: 9362381
[TBL] [Abstract][Full Text] [Related]
20. Emergence of the precore mutant late in chronic hepatitis B infection correlates with the severity of liver injury and mutations in the core region.
Maruyama T; Mitsui H; Maekawa H; Yamada H; Hirayama M; Iino S; Yasuda K; Koike K; Kimura S; Milich DR
Am J Gastroenterol; 2000 Oct; 95(10):2894-904. PubMed ID: 11051365
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
